Nebula Research & Development LLC Increases Stock Position in Keros Therapeutics, Inc. (NASDAQ:KROS)

Nebula Research & Development LLC raised its holdings in shares of Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) by 433.6% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 71,710 shares of the company's stock after purchasing an additional 58,271 shares during the period. Nebula Research & Development LLC owned approximately 0.18% of Keros Therapeutics worth $1,135,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of the business. Walleye Capital LLC bought a new stake in Keros Therapeutics in the 4th quarter worth about $3,129,000. Clearbridge Investments LLC purchased a new stake in Keros Therapeutics in the fourth quarter worth approximately $3,009,000. JPMorgan Chase & Co. grew its position in Keros Therapeutics by 585.9% in the 4th quarter. JPMorgan Chase & Co. now owns 213,431 shares of the company's stock worth $3,379,000 after purchasing an additional 182,314 shares during the period. Federated Hermes Inc. purchased a new stake in Keros Therapeutics during the 4th quarter valued at $1,973,000. Finally, Blue Owl Capital Holdings LP lifted its holdings in shares of Keros Therapeutics by 97.9% during the 4th quarter. Blue Owl Capital Holdings LP now owns 242,633 shares of the company's stock valued at $3,841,000 after buying an additional 120,000 shares during the period. Institutional investors own 71.56% of the company's stock.

Keros Therapeutics Stock Performance

KROS opened at $14.21 on Friday. Keros Therapeutics, Inc. has a fifty-two week low of $9.12 and a fifty-two week high of $72.37. The stock has a market cap of $576.39 million, a price-to-earnings ratio of -2.73 and a beta of 1.39. The firm's fifty day moving average is $11.56 and its 200 day moving average is $27.66.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last released its quarterly earnings data on Wednesday, February 26th. The company reported ($1.14) earnings per share for the quarter, topping analysts' consensus estimates of ($1.36) by $0.22. The firm had revenue of $3.04 million during the quarter, compared to analyst estimates of $37.32 million. Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. On average, equities research analysts predict that Keros Therapeutics, Inc. will post -4.74 earnings per share for the current year.

Analyst Ratings Changes

A number of analysts recently commented on KROS shares. Wedbush reiterated a "neutral" rating and set a $15.00 price objective on shares of Keros Therapeutics in a research report on Tuesday, April 1st. Truist Financial reduced their price target on shares of Keros Therapeutics from $43.00 to $25.00 and set a "buy" rating for the company in a research report on Wednesday, April 9th. Wells Fargo & Company dropped their price objective on shares of Keros Therapeutics from $28.00 to $26.00 and set an "overweight" rating on the stock in a report on Thursday, February 27th. Scotiabank cut their target price on shares of Keros Therapeutics from $44.00 to $41.00 and set a "sector outperform" rating for the company in a research report on Thursday, January 16th. Finally, Cantor Fitzgerald downgraded shares of Keros Therapeutics from an "overweight" rating to a "neutral" rating in a research report on Tuesday, January 21st. Six analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $40.33.

Insiders Place Their Bets

In related news, major shareholder Adar1 Capital Management, Llc acquired 934,258 shares of the company's stock in a transaction on Wednesday, April 9th. The stock was acquired at an average price of $10.13 per share, with a total value of $9,464,033.54. Following the acquisition, the insider now directly owns 4,392,737 shares of the company's stock, valued at approximately $44,498,425.81. This trade represents a 27.01 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this link. 22.90% of the stock is currently owned by corporate insiders.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.

Want to see what other hedge funds are holding KROS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.